The American Society for Radiation Oncology recently welcomed Karen Davis as its first vice president of business development and marketing.
In recognition of Men’s Health Month, UVA Cancer Center is expanding “Stay in the Game,” a community-centered program to raise awareness across Virginia about prostate cancer and the importance of early screening.
The National Comprehensive Cancer Network has launched a continuing education resource called NCCN Guidelines in Practice. This subscription service equips health professionals with continuing education tools to support care decision-making and delivery according to the latest evidence-based, expert consensus-driven recommendations, while earning continuing education and Maintenance of Certification credits for the NCCN Guidelines engagement they are already doing during their daily clinical work.
The Clinic by Cleveland Clinic announced the expansion of Cancer Concierge by Cleveland Clinic—a program connecting cancer patients across the U.S. with oncology subspecialists.
Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.
Johnson & Johnson announced on June 15 new results from the phase II RedirecTT-1 study evaluating the investigational combination of Talvey (talquetamab-tgvs), the first U.S. FDA-approved GPRC5D-directed bispecific antibody, and Tecvayli (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific antibody.
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.
Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.
FDA has approved Zusduri as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
FDA has approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
